Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.21: OTHER EXPENSES PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Consumption of stores, spares and other materials 3,755 3,035 Excise duty 743 562 Clinical trial expenses 1,778 1,808 Other research and development expenses 4,195 3,588 Advertisements 206 233 Commission on sales 163 176 Carriage outwards 2,535 2,494 Other selling expenses 7,730 6,087 Repairs and maintenance Buildings 267 155 Plant and machinery 646 567 Others 1,110 1,037 Power and fuel 2,971 2,728 Legal and professional 2,747 2,347 Travel and conveyance 813 838 Non executive directors’ remuneration 80 80 Foreign exchange loss, net - 1,287 Rent 201 313 Rates and taxes 137 216 CSR and donations* 313 183 Insurance 273 299 Loss on sale of fixed assets, net 120 - Loss on sale of non current investments - 166 Auditors’ remuneration (Refer note 2.28) 14 14 Provision for other than temporary diminution in the value of non current investments - 245 Provision for doubtful debts, net 98 29 Provision / (reversal of provision) for doubtful advances, net 198 (382) Other general expenses 1,817 1,672 32,910 29,777 * Includes an amount of ` 292 incurred during the year ended 31 March 2015 towards various Corporate Social Responsibilty (CSR) activities in accordance with section 135 of the Companies Act, 2013. 2.22: TAX EXPENSE PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Current tax expense Domestic taxes 4,411 4,901 MAT credit entitlement (644) - 3,767 4,901 Deferred tax expense Domestic taxes 38 315 38 315 (a) Pursuant to a favourable order from Income Tax Appellate Tribunal, Hyderabad over a previously litigated matter, the company has reversed a tax provision of ` 684 during the year ended 31 March 2014. 136
Standalone Financial Statements Annual Report 2014 - 15 NOTES TO FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.23: RESEARCH AND DEVELOPMENT EXPENSES Details of research and development expenses (excluding depreciation and amortisation expense) incurred during the year and included under various heads of expenditure are given below: PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Employee benefits expense (included in note 2.19) 2,422 2,350 Other expenses (included in note 2.21) Clinical trial expenses 1,778 1,808 Materials and consumables 2,701 2,089 Power and fuel 134 147 Other research and development expenses 4,195 3,588 11,230 9,982 2.24: EARNINGS PER SHARE (EPS) PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 Earnings Profit for the year 16,794 19,328 Shares Number of shares at the beginning of the year 170,108,868 169,836,475 Add: Equity shares issued on exercise of vested stock options 272,306 272,393 Total number of equity shares outstanding at the end of the year 170,381,174 170,108,868 Weighted average number of equity shares outstanding during the year – Basic 170,314,506 170,044,518 Add: Weighted average number of equity shares arising out of outstanding stock options (net of the stock options forfeited) that have dilutive effect on the EPS 742,463 813,171 Weighted average number of equity shares outstanding during the year – Diluted 171,056,969 170,857,689 Earnings per share of par value `5/- – Basic (`) 98.60 113.67 Earnings per share of par value `5/- – Diluted (`) 98.18 113.13 2.25: CONTINGENT LIABILITIES AND COMMITMENTS PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 (A) Contingent liabilities: Guarantees: (a) Issued by the Company on behalf of subsidiaries, associates and joint ventures 10,419 13,836 Claims against the Company not acknowledged as debts in respect of: (a) Income tax matters, under dispute (refer note ‘k’ below) 1,181 1,264 (b) Excise matters (including service tax), under dispute (refer note ‘i’ below) 402 633 (c) Sales tax matters, under dispute (refer note ‘j’ below) 317 319 (d) DPCO matters The Company is contesting various demands for payment to the credit of the Drug Prices Equalisation Account under Drugs (Price Control) Order, 1995 for few of its products, including norfloxacin. Based on its best estimate, the Company has made a provision for the potential liability related to the overcharged amount including the interest thereon and believes that the possibility of any liability that may arise on account of penalty on this demand is not probable. In the event the Company is unsuccessful in its litigation in the Supreme Court, it will be required to remit the sale proceeds in excess of the notified selling prices to the Government of India with interest and including penalties, if any, which amounts are not readily ascertainable. 137
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88: Statutory Reports • Board’s Rep
Page 111 and 112: Standalone Financial Statements Ann
Page 137: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 189 and 190:
Consolidated Financial Statements A
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?